MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
78.88
+0.16 (+0.20%)
At close: 4:00PM EDT

78.35 -0.53 (-0.67%)
After hours: 7:32PM EDT

Stock chart is not supported by your current browser
Previous Close78.72
Open78.36
Bid78.35 x 2200
Ask78.89 x 800
Day's Range78.25 - 79.27
52 Week Range58.03 - 83.85
Volume7,644,224
Avg. Volume10,364,098
Market Cap203.088B
Beta (3Y Monthly)0.31
PE Ratio (TTM)24.91
EPS (TTM)3.17
Earnings DateJul 30, 2019
Forward Dividend & Yield2.20 (2.80%)
Ex-Dividend Date2019-03-14
1y Target Est88.07
Trade prices are not sourced from all markets
  • CNBC4 hours ago

    Stocks making the biggest moves after hours: GM, Snap, Merck and more

    Shares of Merck & Co MRK dropped as much as 9% in extended trading on Monday, before erasing those losses, after the pharmaceutical company announced that its medication Keytruda failed to meet expectations in phase 3 of the drug's trial. Shares of Snap SNAP ticked slightly higher after the company announced it has named a new chief financial officer to take over for interim CFO Lara Sweet, effective immediately. The social media company promoted Derek Andersen, Snap's current vice president of finance, to permanently fill the position of chief financial officer.

  • Reuters4 hours ago

    Merck's Keytruda fails as monotherapy in breast cancer study

    Merck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the drug as a standalone treatment in patients with an aggressive type of breast cancer. Keytruda, among a class of medicines called PD-1 inhibitors, did not meet the main goal of helping patients live longer, when compared to chemotherapy. The treatment will continue to be studied in earlier stages of the disease and in combination with chemotherapy in patients with triple negative breast cancer, the company said.

  • MarketWatch4 hours ago

    Merck shares slip as Keytruda fails another clinical trial

    Merck & Co. shares slipped in the extended session Monday after the drug maker said its cancer treatment Keytruda failed to meet clinical endpoints in another late-stage study. Merck shares declined 0.7% after hours, following a 0.2% rise to close the regular session at $78.88. In a Phase 3 clinical study, Merck said Keytruda "did not meet its pre-specified primary endpoint of superior overall survival" compared with chemotherapy in a subset of breast cancer patients. In late April, Merck said Keytruda did not show significant improvement over chemotherapy in gastric cancer patients. For the year, Merck shares are up 3.2%, compared with a 13.3% rise in the S&P 500 index .

  • Business Wire5 hours ago

    Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer

    Merck , known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-119 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the second- or third-line treatment of patients with metastatic triple-negative breast cancer did not meet its pre-specified primary endpoint of superior overall survival compared to chemotherapy .

  • Reuters7 hours ago

    U.S. Supreme Court gives Merck another shot to avoid Fosamax lawsuits

    The U.S. Supreme Court on Monday gave Merck & Co a new opportunity to avoid lawsuits accusing the company of failing to properly warn patients of debilitating thigh-bone fractures from taking its osteoporosis drug Fosamax, throwing out a lower court decision that had revived the litigation. The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit Court of Appeals to reconsider its decision to let the lawsuits proceed even though the Food and Drug Administration had rebuffed Merck when the company sought to add a warning to Fosamax's label about fracture risk.

  • Why Merck (MRK) is a Great Dividend Stock Right Now
    Zacks12 hours ago

    Why Merck (MRK) is a Great Dividend Stock Right Now

    Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

  • AbbVie's Brain Cancer Candidate Fails in Phase III Study
    Zacks12 hours ago

    AbbVie's Brain Cancer Candidate Fails in Phase III Study

    AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.

  • Reuters13 hours ago

    CPPIB buys partial Keytruda royalty interest from British charity LifeArc

    Canada's largest pension fund said the deal was an ideal investment for its global intellectual property programme as Keytruda, an immunotherapy treatment for different cancer types, has shown strong sales growth worldwide. Keytruda, which works by increasing the ability of the patient's immune system to help detect and fight tumour cells, is approved for use in 85 countries and the drug is expected to bring more than $10 billion for Merck this year, according to IBES data from Refinitiv.

  • Why Stock Buybacks Are Soaring Near Record Highs Amid Trade War
    Investopedia16 hours ago

    Why Stock Buybacks Are Soaring Near Record Highs Amid Trade War

    The largest U.S. companies are repurchasing their shares at a brisk pace, and 1Q 2019 may prove to be the second-biggest quarter ever for buybacks.

  • Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs
    Zacks4 days ago

    Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs

    FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs

  • Reuters4 days ago

    Bayer bets on 'silver bullet' defense in Roundup litigation; experts see hurdles

    Bayer AG plans to argue that a $2 billion jury award and thousands of U.S. lawsuits claiming its glyphosate-based weed killer Roundup causes cancer should be tossed because a U.S. regulatory agency said the herbicide is not a public health risk. Some legal experts believe Bayer will have a tough time convincing appellate courts to throw out verdicts and lawsuits on those grounds. Bayer has a better shot if a business-friendly U.S. Supreme Court takes up the case, experts said.

  • Reuters4 days ago

    Bayer bets on 'silver bullet' defence in Roundup litigation; experts see hurdles

    Bayer AG plans to argue that a $2 billion jury award and thousands of U.S. lawsuits claiming its glyphosate-based weed killer Roundup causes cancer should be tossed because a U.S. regulatory agency said the herbicide is not a public health risk. Some legal experts believe Bayer will have a tough time convincing appellate courts to throw out verdicts and lawsuits on those grounds. Bayer has a better shot if a business-friendly U.S. Supreme Court takes up the case, experts said.

  • Sarah Ketterer's Top 5 New Buys
    GuruFocus.com4 days ago

    Sarah Ketterer's Top 5 New Buys

    Causeway Capital Management leader Sarah Ketterer (Trades, Portfolio) revealed 10 new positions when she released her first-quarter portfolio earlier this week. Warning! GuruFocus has detected 7 Warning Signs with LIN. Based on these criteria, Ketterer's top five new buys for the quarter were Linde PLC (LIN), Merck & Co. Inc. (MRK), Gerdau SA (GGB), the iShares MSCI Emerging Index Fund (EEM) and Telefonica Brasil SA (VIV).

  • ImmunoGen Plunges as FDA Recommends New Study for Lead Drug
    Zacks4 days ago

    ImmunoGen Plunges as FDA Recommends New Study for Lead Drug

    FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.

  • Gardasil and Bridion: Merck’s High-Growth Assets
    Market Realist5 days ago

    Gardasil and Bridion: Merck’s High-Growth Assets

    Comparing MRK’s and ABBV’s Outlook: Which Is the Better Pick?(Continued from Prior Part)Bridion growth trendsIn the first quarter, sales of Merck’s (MRK) hospital acute care drug, Bridion, rose 25% YoY (year-over-year) on a reported basis and

  • Business Wire5 days ago

    New Research from Merck’s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting

    First-Time Data from POLO Trial Evaluating LYNPARZA® in Germline BRCA-Mutated Metastatic Pancreatic Cancer in Plenary Session and ASCO Press Program

  • Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer
    Zacks5 days ago

    Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer

    Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.

  • Keytruda’s Label Expansion and Geographic Market Trends
    Market Realist5 days ago

    Keytruda’s Label Expansion and Geographic Market Trends

    Comparing MRK’s and ABBV’s Outlook: Which Is the Better Pick?(Continued from Prior Part)International market performanceIn its first quarter, Merck’s (MRK) ex-US Keytruda sales rose 69% YoY (year-over-year) to ~$985 million, and lung

  • 4 Dow Stocks to Buy on the Dip Despite Market Volatility
    Zacks6 days ago

    4 Dow Stocks to Buy on the Dip Despite Market Volatility

    After an impressive bull run in the first four months of this year, it seems volatility is once again ready to rear its ugly face in Wall Street.

  • Benzinga6 days ago

    The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 14) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Avedro Inc ...

  • Keytruda: Merck’s Key Growth Driver in Fiscal 2019
    Market Realist6 days ago

    Keytruda: Merck’s Key Growth Driver in Fiscal 2019

    Comparing MRK’s and ABBV’s Outlook: Which Is the Better Pick?(Continued from Prior Part)Keytruda’s growth trendsIn its first-quarter conference call, Merck (MRK) highlighted that Keytruda was approved in 18 indications across 11 tumor types

  • How Do Analysts See Merck & Co., Inc. (NYSE:MRK) Performing In The Year Ahead?
    Simply Wall St.6 days ago

    How Do Analysts See Merck & Co., Inc. (NYSE:MRK) Performing In The Year Ahead?

    As Merck & Co., Inc. (NYSE:MRK) announced its earnings release on 31 March 2019, analysts seem fairly confident, as a...

  • How MRK’s and ABBV’s EPS Growth Compares
    Market Realist6 days ago

    How MRK’s and ABBV’s EPS Growth Compares

    Comparing MRK’s and ABBV’s Outlook: Which Is the Better Pick?(Continued from Prior Part)EPS guidanceIn its first-quarter press release, Merck (MRK) raised its GAAP fiscal 2019 EPS guidance from $3.97–$4.12 to $4.02–$4.14, and its non-GAAP